Mark D. Starr

2.8k total citations
49 papers, 1.9k citations indexed

About

Mark D. Starr is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark D. Starr has authored 49 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 19 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark D. Starr's work include Angiogenesis and VEGF in Cancer (8 papers), TGF-β signaling in diseases (8 papers) and Colorectal Cancer Treatments and Studies (8 papers). Mark D. Starr is often cited by papers focused on Angiogenesis and VEGF in Cancer (8 papers), TGF-β signaling in diseases (8 papers) and Colorectal Cancer Treatments and Studies (8 papers). Mark D. Starr collaborates with scholars based in United States, Hong Kong and Canada. Mark D. Starr's co-authors include Andrew B. Nixon, Mervin C. Yöder, Susan Mineka, S.A. Johnson, Xiaodong Xie, Michael J. Ferkowicz, W. Christopher Shelley, Weiming Li, Paul R. Morrison and Herbert I. Hurwitz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Mark D. Starr

48 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark D. Starr United States	21	855	606	571	419	253	49	1.9k
Andreas H. Kottmann United States	16	1.6k 1.9×	1.3k 2.2×	1.4k 2.4×	334 0.8×	138 0.5×	19	3.8k
Roderick T. Bronson United States	7	1.6k 1.8×	315 0.5×	380 0.7×	237 0.6×	320 1.3×	7	3.0k
Andrea Hellwig Germany	29	1.6k 1.9×	285 0.5×	546 1.0×	800 1.9×	268 1.1×	44	2.7k
Daniel B. Constam Switzerland	34	3.3k 3.8×	519 0.9×	599 1.0×	453 1.1×	316 1.2×	64	4.4k
Guy Froyen Belgium	27	1.6k 1.9×	313 0.5×	287 0.5×	162 0.4×	208 0.8×	85	2.8k
Barbara Moepps Germany	27	1.0k 1.2×	1.1k 1.8×	1.3k 2.3×	438 1.0×	118 0.5×	54	3.1k
Alan Y. Sakaguchi United States	18	2.0k 2.3×	429 0.7×	296 0.5×	202 0.5×	242 1.0×	39	3.5k
Eva Klopocki Germany	34	2.3k 2.6×	174 0.3×	442 0.8×	204 0.5×	294 1.2×	103	3.7k
Paul W. Cook United States	22	1.0k 1.2×	408 0.7×	574 1.0×	398 0.9×	178 0.7×	31	1.9k
Gary Brown United States	12	2.1k 2.5×	301 0.5×	410 0.7×	193 0.5×	226 0.9×	14	3.0k

Countries citing papers authored by Mark D. Starr

Since Specialization

Citations

This map shows the geographic impact of Mark D. Starr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Starr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Starr more than expected).

Fields of papers citing papers by Mark D. Starr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark D. Starr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Starr. The network helps show where Mark D. Starr may publish in the future.

Co-authorship network of co-authors of Mark D. Starr

This figure shows the co-authorship network connecting the top 25 collaborators of Mark D. Starr. A scholar is included among the top collaborators of Mark D. Starr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark D. Starr. Mark D. Starr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hwang, Joyce K., Eda K. Holl, Yuan Wu, et al.. (2025). Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy. JCI Insight. 10(4). 1 indexed citations

Nixon, Andrew B., Yingmiao Liu, Qian Yang, et al.. (2024). Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab. Prostate Cancer and Prostatic Diseases. 28(2). 355–362. 2 indexed citations

Siamakpour‐Reihani, Sharareh, Jing Lyu, Yi Ren, et al.. (2022). Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia. PLoS ONE. 17(6). e0268963–e0268963.

Monavarian, Mehri, Kathleen O’Connell, Diego Altomare, et al.. (2022). Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer. Cell Reports. 40(4). 111066–111066. 27 indexed citations

Weinsheimer, Shantel, Jeffrey Nelson, Ludmila Pawlikowska, et al.. (2021). Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformations. Orphanet Journal of Rare Diseases. 16(1). 372–372. 9 indexed citations

Liu, Yingmiao, Jing Lyu, Kirsten B. Burdett, et al.. (2020). Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. Molecular Cancer Therapeutics. 19(10). 2146–2154. 15 indexed citations

Liu, Yingmiao, Mark D. Starr, John C. Brady, et al.. (2018). Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105. Molecular Cancer Therapeutics. 17(10). 2248–2256. 15 indexed citations

Hatch, Ace J., Alexander B. Sibley, Mark D. Starr, et al.. (2016). Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Medicine. 5(9). 2249–2260. 17 indexed citations

Huang, Jennifer J., Mark D. Starr, Andrew B. Nixon, et al.. (2016). TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. Carcinogenesis. 37(11). 1041–1051. 78 indexed citations

10.

Liu, Yingmiao, Mark D. Starr, John C. Brady, et al.. (2015). Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus. Molecular Cancer Therapeutics. 14(4). 1048–1056. 18 indexed citations

11.

Huang, Jennifer J., Catherine E. Gatza, Jian Chen, et al.. (2014). Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion. Molecular Biology of the Cell. 25(16). 2320–2332. 38 indexed citations

12.

Gatza, Catherine E., et al.. (2014). The Balance of Cell Surface and Soluble Type III TGF-β Receptor Regulates BMP Signaling in Normal and Cancerous Mammary Epithelial Cells. Neoplasia. 16(6). 489–500. 22 indexed citations

13.

Uronis, Hope E., Jingquan Jia, Johanna C. Bendell, et al.. (2014). A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 75(2). 343–352. 8 indexed citations

14.

Bitting, Rhonda L., Patrick Healy, Patricia Creel, et al.. (2013). A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 12(4). 241–250. 24 indexed citations

15.

Nixon, Andrew B., Herbert Pang, Mark D. Starr, et al.. (2013). Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance). Clinical Cancer Research. 19(24). 6957–6966. 82 indexed citations

16.

Nixon, Andrew B., Susan Halabi, Ivo Shterev, et al.. (2013). Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).. Journal of Clinical Oncology. 31(15_suppl). 4520–4520. 17 indexed citations

17.

Teoh, Deanna, David J. Adams, L. Grace, et al.. (2011). Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. Gynecologic Oncology. 121(1). 187–192. 32 indexed citations

18.

Kong, Young‐Yun, Hiroshi Nishina, Kerry Tedford, et al.. (1998). Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor. Current Biology. 8(10). 554–S3. 380 indexed citations

19.

Starr, Mark D., Julio C. Rojas, Rodrigo Zeledón, David W. Hird, & Tim E. Carpenter. (1991). Chagas' Disease: Risk Factors for House Infestation by Triatoma dimidiata, the Major Vector of Trypanosoma cruzi in Costa Rica. American Journal of Epidemiology. 133(7). 740–747. 43 indexed citations

20.

Kasman, L. H., John P. Hughes, George H. Stabenfeldt, Mark D. Starr, & Bill L. Lasley. (1988). Estrone sulfate concentrations as an indicator of fetal demise in horses. American Journal of Veterinary Research. 49(2). 184–187. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact